Company intelligence / Profile preview

Mirati Therapeutics

San Diego, California, United Statesnews.bms.com ↗

Ownership: Public · MRTX
Employees: ~600
Development stage: Commercial

Overview

Mirati Therapeutics developed KRAZATI® (adagrasib), a KRASG12C inhibitor approved for NSCLC. Other programs include MRTX1133 targeting KRASG12D in early clinical trials, and additional assets such as sitravatinib and MRTX1719. Sitravatinib failed its phase 3 trial in NSCLC and is no longer being developed by Mirati for that indication. The pipeline includes both marketed and investigational drugs focused on genetically defined cancers.[6][9]

Therapeutic areas: Oncology
Modalities: Small molecules[2][1]Targeted therapies[1][2]
Industry: Biotech

Drug pipeline

4 assets

adagrasib

Commercial

Indications: Non-small cell lung cancer

3 more assets in the full pipeline.

Request access →

Partnerships

Zai LabBeiGeneSanofiBoehringer IngelheimNovartisBristol Myers Squibb [2]

Financials

Market cap: $4.1B
Total revenue: $16.4M
Enterprise value: $3.1B

Beyond the preview

Go deeper on Mirati Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mirati Therapeutics.

Explore the full profile